Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578, ONO-4538, Docetaxel and Ramucirumab in Metastatic Non-small Cell Lung Cancer
NCT06542731Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-4578 in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 21 days and Adverse event. Started Jun 2021; status: completed.
02
Drugs
ONO-4578
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06542731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542731.